首页> EMBO molecular medicine> Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies.

Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post-translational modification: prospective placebo-controlled clinical studies.

导出 OA

翻译打印收藏纠错

第一作者： Jérémie,Decalf

第一单位： The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France INSERM U818, Paris, France.

作者： Jérémie,Decalf ^[1] ; Kristin V,Tarbell ^[2] ; Armanda,Casrouge ^[1] ; Jeffrey D,Price ^[2] ; Grace,Linder ^[2] ; Estelle,Mottez ^[3] ; Philippe,Sultanik ^[4] ; Vincent,Mallet ^[4] ; Stanislas,Pol ^[4] ; Darragh,Duffy ^[5] ; Matthew L,Albert ^[6]

作者单位： The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France INSERM U818, Paris, France. ^[1] Diabetes Endocrinology and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA. ^[2] Center for Human Immunology, Institut Pasteur, Paris, France. ^[3] Département d'Hépatologie, AP-HP, Hôpital Cochin, Université Paris Descartes, INSERM UMS20, Institut Pasteur, Paris, France. ^[4] The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France INSERM U818, Paris, France Center for Human Immunology, Institut Pasteur, Paris, France darragh.duffy@pasteur.fr albertm@pasteur.fr. ^[5] The Laboratory of Dendritic Cell Immunobiology, Institut Pasteur, Paris, France INSERM U818, Paris, France Center for Human Immunology, Institut Pasteur, Paris, France Department of Cancer Immunotherapy, Genentech, South San Francisco, CA, USA darragh.duffy@pasteur.fr albertm@pasteur.fr. ^[6]

关键词 CXCL10 DPP4 chemokines clinical study post‐translational modifications